- Starpharma advances a new internal DEP® candidate, DEP® gemcitabine, into development
- DEP® gemcitabine demonstrated significantly enhanced anti-tumour activity compared with Gemzar® (gemcitabine), both alone and in combination with Nab‑paclitaxel (Abraxane®), in a human pancreatic cancer model
- Gemzar® (gemcitabine), used alone or in combination with Abraxane®, is the current standard of care therapy for pancreatic cancer
- A patent has been filed for Starpharma’s proprietary DEP® gemcitabine, providing coverage to 2040
Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today
announced results for its next internal development candidate, DEP® gemcitabine.
Starpharma’s proprietary DEP® gemcitabine demonstrated significantly enhanced anti‑tumour activity compared with Gemzar® (gemcitabine), both alone and in combination with Nab-paclitaxel (Abraxane®)
in a preclinical human pancreatic cancer model. This data has formed
the basis of a new patent application, which will provide coverage over
DEP® gemcitabine to 2040. DEP® gemcitabine is one of several internal DEP® candidates under preclinical development by Starpharma.
DEP® gemcitabine is a DEP® version of Lilly’s Gemzar® (gemcitabine) - a well-established anti-cancer drug, which had peak sales of US$1.7 billion. Gemzar®
(gemcitabine) is one of the leading chemotherapeutic drugs used to
treat pancreatic cancer. It can be administered as a monotherapy or in
combination with other therapies such as Abraxane®.
DEP® gemcitabine demonstrated significantly improved anti-tumour activity, compared to Gemzar®,
the standard form of gemcitabine, in the human pancreatic cancer
xenograft model (p<0.0001). When used in combination with Abraxane®, DEP® gemcitabine significantly outperformed a combination of Gemzar® (gemcitabine) and Abraxane (p<0.005).
About Starpharma’s DEP® platform
Starpharma’s internal pipeline includes a number of pre-clinical DEP® candidates, including DEP® gemcitabine, as well as three clinical stage assets - DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan. A fourth DEP® drug, DEP® AZD0466 (AstraZeneca’s Bcl2/xL DEP® program), is expected to enter the clinic later this year.